Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARTH NASDAQ:IDXG NASDAQ:NVIV NASDAQ:OBLN OTCMKTS:RDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.12$0.16▼$1.57$763K4.024,068 shsN/AIDXGInterpace Biosciences$0.85+7.6%$8.06$2.57▼$10.42$3.75M0.766,816 shs3,060 shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsOBLNObalon Therapeutics$6.45-11.6%$4.22$0.66▼$10.77$64.64M-1.237.68 million shs68,982 shsRDGLAdvanced Medical Isotope$0.09-0.5%$0.11$0.04▼$0.18$42.27M1.141.31 million shs1.28 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%0.00%0.00%-99.84%IDXGInterpace Biosciences0.00%+0.01%-20.19%+11.28%-46.61%NVIVInVivo Therapeutics0.00%0.00%0.00%0.00%0.00%OBLNObalon Therapeutics0.00%-8.18%-47.86%+154.36%+4,250.42%RDGLAdvanced Medical Isotope-0.54%-7.96%+6.44%-30.35%-36.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.12$0.16▼$1.57$763K4.024,068 shsN/AIDXGInterpace Biosciences$0.85+7.6%$8.06$2.57▼$10.42$3.75M0.766,816 shs3,060 shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsOBLNObalon Therapeutics$6.45-11.6%$4.22$0.66▼$10.77$64.64M-1.237.68 million shs68,982 shsRDGLAdvanced Medical Isotope$0.09-0.5%$0.11$0.04▼$0.18$42.27M1.141.31 million shs1.28 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%0.00%0.00%-99.84%IDXGInterpace Biosciences0.00%+0.01%-20.19%+11.28%-46.61%NVIVInVivo Therapeutics0.00%0.00%0.00%0.00%0.00%OBLNObalon Therapeutics0.00%-8.18%-47.86%+154.36%+4,250.42%RDGLAdvanced Medical Isotope-0.54%-7.96%+6.44%-30.35%-36.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTHArch Therapeutics 0.00N/AN/AN/AIDXGInterpace Biosciences 0.00N/AN/AN/ANVIVInVivo Therapeutics 0.00N/AN/AN/AOBLNObalon Therapeutics 0.00N/AN/AN/ARDGLAdvanced Medical Isotope 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTHArch Therapeutics$80K0.00N/AN/A($2.43) per share0.00IDXGInterpace Biosciences$40.21M0.09$0.43 per share1.99($14.16) per share-0.06NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/AOBLNObalon Therapeutics$1.59M40.66N/AN/A$0.60 per share10.75RDGLAdvanced Medical Isotope$30K1,401.53N/AN/A($0.02) per share-4.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTHArch Therapeutics-$6.98MN/A0.00N/AN/A-8,257.70%N/A-730.22%N/AIDXGInterpace Biosciences$800KN/A0.00∞N/A10.39%-8.09%37.14%N/ANVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/AOBLNObalon Therapeutics-$12.33MN/AN/A∞N/A-776.76%-161.38%-83.58%N/ARDGLAdvanced Medical Isotope-$2.91MN/A0.00∞N/A-6,401.92%N/A-139.36%11/11/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTHArch TherapeuticsN/AN/AN/AN/AN/AIDXGInterpace BiosciencesN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/AOBLNObalon TherapeuticsN/AN/AN/AN/AN/ARDGLAdvanced Medical IsotopeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTHArch TherapeuticsN/A0.100.01IDXGInterpace BiosciencesN/A0.590.59NVIVInVivo TherapeuticsN/A14.3014.30OBLNObalon TherapeuticsN/A1.861.86RDGLAdvanced Medical IsotopeN/A28.7828.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTHArch Therapeutics6.91%IDXGInterpace Biosciences5.73%NVIVInVivo Therapeutics13.78%OBLNObalon Therapeutics18.64%RDGLAdvanced Medical IsotopeN/AInsider OwnershipCompanyInsider OwnershipARTHArch Therapeutics4.50%IDXGInterpace Biosciences5.50%NVIVInVivo Therapeutics2.45%OBLNObalon Therapeutics8.10%RDGLAdvanced Medical Isotope18.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTHArch Therapeutics104.74 million4.53 millionNot OptionableIDXGInterpace Biosciences1524.41 million4.17 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableOBLNObalon Therapeutics210.02 millionN/ANot OptionableRDGLAdvanced Medical Isotope1454.55 million370.46 millionNot OptionableIDXG, NVIV, RDGL, ARTH, and OBLN HeadlinesRecent News About These CompaniesVivos Inc. Demonstrates Precision in Precision Radionuclide TherapySeptember 8, 2025 | globenewswire.comVivos Inc Files Critical Patent For Hydrogel Electron Beam SterilizationSeptember 3, 2025 | globenewswire.comAdvanced Medical Isotope Corporation (OTCMKTS:RDGL) Short Interest Down 80.4% in JulyAugust 17, 2025 | marketbeat.comInvestigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDAAugust 14, 2025 | globenewswire.comVivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo ClinicJuly 14, 2025 | globenewswire.comVivos Inc. Certifies University of Florida Veterinary Hospital for IsoPet® Precision Radionuclide Therapy™May 15, 2025 | globenewswire.comVivos Inc.May 8, 2025 | marketwatch.comVivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025April 23, 2025 | globenewswire.comVivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™April 15, 2025 | globenewswire.comVivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion PlansFebruary 4, 2025 | finance.yahoo.comVivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics NationwideDecember 27, 2024 | markets.businessinsider.comVivos Inc.'s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics NationwideDecember 26, 2024 | globenewswire.comVivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical TrialDecember 23, 2024 | globenewswire.comVivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3November 14, 2024 | proactiveinvestors.comVivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTMOctober 18, 2024 | globenewswire.comVivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to ExoticsSeptember 30, 2024 | finance.yahoo.comVivos Inc. (RDGL) Stock Price, News, Quote & History - Yahoo FinanceAugust 25, 2024 | finance.yahoo.comVivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDAJuly 29, 2024 | globenewswire.comVivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical TrialsJune 28, 2024 | globenewswire.comVivos Inc. (RDGL) Latest Stock News & Headlines - Yahoo FinanceMay 15, 2024 | finance.yahoo.comBarchart’s Hot Penny Stocks Screener Identifies Opportunity in Vivos (RDGL)May 3, 2024 | msn.comMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025MP Materials: How One Move Redefined the U.S. Magnet Supply ChainBy Jeffrey Neal Johnson | August 27, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025IDXG, NVIV, RDGL, ARTH, and OBLN Company DescriptionsArch Therapeutics OTCMKTS:ARTHArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Interpace Biosciences NASDAQ:IDXGInterpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.InVivo Therapeutics NASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.Obalon Therapeutics NASDAQ:OBLNObalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.Advanced Medical Isotope OTCMKTS:RDGL$0.09 0.00 (-0.54%) As of 09/15/2025 03:59 PM EasternVivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
